Multidisciplinary management of DMD
Discover the best practices for the multidisciplinary management of Duchenne Muscular Dystrophy (DMD) with insights from experts Nadia Merchant and Laurent Servais. They will discuss the standard of care for DMD patients and how to manage the various clinical manifestations of the disease.
Register to access
Tell others what you are learning about
General information
Title: Multidisciplinary management of DMD
Release date: February 6th 2025
Estimated time to complete activity: 15 minutes
Target audience
This activity is intended for pediatric neurologists, primary care physicians, pediatricians, geneticists, genetic counselors, neuromuscular specialists, nurse practitioners, pulmonologists, cardiologists, endocrinologists, orthopedists and physical therapists engaged in the care of patients with DMD.
Learning objectives
After completing the module, you will be able to:
- Describe the established standard of care for patients diagnosed with DMD
- Explain multidisciplinary team approaches, including potential challenges, for optimizing patient management and improving quality of life
- Discuss recommendations to refine DMD treatment strategies, continuity of care, and patient monitoring
Faculty
- Nadia Merchant
Assistant Professor of Pediatrics, Pediatric Endocrinology and Medical Genetics, Children’s Health/University of Texas Southwestern, Texas, USA - Laurent Servais
Professor of Paediatrics Neuromuscular Diseases at the University of Oxford and part-time Professor at the University of Liege, Belgium
Disclosures
- Nadia Merchant
Consultant/Advisory Board: Pfizer, Catalyst and BioMarin for Growth Advisory Board - Laurent Servais
Grants/research support: Roche, Biogen, Novartis, Sysnav, Zentech, Scholar Rock, BioHaven
Honoraria or consultation fees: Roche, Biogen-Novartis, Sysnav, Zentech, Scholar Rock, BioHaven, Pfizer, Sarepta, Dyne, Astellas, Cerebral Therapeutics, Illumina, Altana, Solid, Regenex Bio, Santhera, Italfarmaco
